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QUESTIONS
1. What was the rationale for conducting this study?
2. How do systemic steroids affect pregnancy?
3. How did the investigators carry out their study?
4. What were the results of the study?
5. What were the conclusions and clinical implications of the study?
Not uncommonly, dermatologists are presented with the following scenario. A long-
standing patient with atopic dermatitis informs you that she is pregnant. For the 
safety of her unborn child, you discontinue systemic medications but instruct her 
to continue using her topical steroids. Does use of topical steroids confer a risk to 
the fetus, and, if so, what is the risk? This clinical situation was, in part, the rationale 
behind the study by Chi and colleagues (2011, this issue), who utilized two clinical and 
administrative databases in the United Kingdom (the UK General Practice Research 
Database and a pregnancy-specific Mother–Baby Link data set) to address this ques-
tion. Previous studies were limited by sample size and other data issues, leading to 
inconclusive results (Chi et al., 2010).
The most studied systemic steroid in pregnancy is dexamethasone, used 
antenatally for lung maturation in preterm infants and to prevent congenital adrenal 
hyper plasia in at-risk fetuses (Seckl, 2004). In these contexts, a single dose of systemic 
synthetic corticosteroids reduces infant mortality, intraventricular hemorrhage, and 
neurological and developmental issues; however, infants who received multiple 
courses of corticosteroids have an increased risk of neonatal sepsis and decreased head circumference, weight, 
breathing rate, and heart rate (Mariotti et al., 2004). Animal studies have revealed similar findings (Jobe et al., 1998).
In this issue, Chi et al. (2011) report that the use of potent or super potent topical corticosteroids in women dur-
ing pregnancy was associated with a significantly increased risk of giving birth to low-birth-weight infants, but use 
of these topical corticosteroids was not associated with orofacial cleft, preterm delivery, or fetal death. Although the 
results of this work, which involved the evaluation of the outcomes of tens of thousands of pregnant women exposed 
to topical corticosteroids, are informative, the retrospective nature of the database and the assumptions made sug-
gest that further exploration of these relationships is warranted. Through the following questions, we examine this 
paper in greater detail. For brief answers, please refer to the supplementary information online <http://www.nature.
com/jid/journal/v131/n4/suppinfo/jid201125s1.html>.
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